Xinda Securities·2026-03-24 09:05Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 77.66 billion yuan in 2025, representing a year-on-year increase of 3.55%, and a net profit attributable to shareholders of 2.98 billion yuan, up 5.21% year-on-year [3][4] - The company plans to distribute a cash dividend of 1.38 billion yuan, with a payout ratio of 46.32%, marking a historical high for dividend distribution [4] - The company is focusing on internationalization, research and development innovation, external growth, and market value management as part of its strategic deployment [3] Financial Performance Summary - In 2025, the pharmaceutical commercial revenue reached 56.98 billion yuan, an increase of 6.21% year-on-year, while the revenue from natural beverages was 9.67 billion yuan, down 0.34% [3] - The company’s net profit for Q4 2025 was -0.33 billion yuan, a decrease of 1.07% year-on-year, indicating short-term profit pressure [3] - The company’s total revenue is projected to grow to 80.93 billion yuan in 2026, with a net profit of 3.15 billion yuan, reflecting a year-on-year growth of 5.7% [6] Strategic Developments - The company has established strategic partnerships for international operations with firms in Saudi Arabia, Japan, and South Korea, among others, to enhance its global presence [3] - In terms of R&D, the company has made significant progress with several new drug projects entering critical clinical trials and approvals [3] - The company has also engaged in external growth by acquiring stakes in other firms, enhancing its market position in East China [3]